Sponsor
University of Nebraska
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03568630
Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease.
The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.
The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.
Intervention
Hemoglobin A1c, Mixed Meal Tolerance Test, Other exploratory blood biomarkers
Condition
Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Investigators
Kelsey A. Klute, MD, Suzanne M Wessling, RN, BSN